GemPharmatech Co. Ltd. Founded
Parent company GemPharmatech Co. Ltd. established with headquarters in Nanjing, China.
Knockout All Project (KOAP) Initiated
Knockout All Project (KOAP) initiated to establish a comprehensive library of knockout (KO) and conditional knockout (cKO) mice for all protein coding genes in the mouse genome.
Humanized Model Development
Developed humanized animal models and opened a branch in Changzhou to expand production capacity.
GemPharmatech US Launched
Obtained germ-free animal production license, expanded production base by opening facilities in Chengdu and Guangzhou, and launched GemPharmatech LLC to serve the North American and European markets.
17,000+ Genetically Engineered Mouse Models
Library reached 17,000+ genetically engineered mouse models (GEMMs), expanded productdion capacity by opening facilities in Beijing, China.
Mark W. Moore, PhD
Chief Executive Officer
Mark is a pioneer in the use of genetically modified mice for pharmaceutical and basic research. He has worked in immunology, oncology, animal model construction and gene editing. Before joining GemPharmatech, he was a co-founder and CSO of Deltagen, the first high-throughput gene KO and target development company, and later served as the Executive Director of the International Mouse Phenotyping Consortium (IMPC). He received his Ph.D. in Biology from Brandeis University studying antibody gene recombination using transgenic mice.
Zhiying Li, PhD
Director, Life Science and Technology
Zhiying is a trained neuroscientist with a doctoral degree from Harvard University. She conducted her postdoctoral research at Rockefeller University. Prior to joining GemPharmatech, she worked at Taconic Biosciences, providing scientific support to both commercial products and scientific services. She is a firm believer in ethical use of research animals and their invaluable contribution to biomedical research for the benefit of human health.
Senior Director, Sales and Marketing
Brook has held senior marketing executive positions in a number of life sciences companies and has over 20 years of experience in the industry. Her prior experience includes working with companies in clinical trial technology, the clinical CRO space, and CDMO space. She is responsible for leading GemPharmatech’s marketing and sales operations in the US.
Santi Suryani Chen, PhD
Associate Director, Immunology and Oncology
Santi is a research scientist and business development professional with over 10 years of experience in autoimmune disease, immunology, and oncology disease areas. Santi received her training in human B cell development at the Garvan Institute of Medical Research Australia in Immunology, followed by a postdoctoral fellowship at the Children’s Cancer Institute Australia, focusing on pediatric leukemia and therapies. Her projects include testing agents' efficacy and mechanisms such as navitoclax, venetoclax, and selumetinib. Her research projects resulted in multiple publications in journals such as Blood and Journal of Immunology and national/international awards.